Could AbbVie be a steal for investors as new meds take off? by Kyle Blankenship Friday, November 22, 2019 With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Allergan rolls new Vraylar ads focused on bipolar depression by Beth Snyder Bulik Monday, September 9, 2019 Allergan depicts the ups and downs of bipolar disorder with an elevator metaphor in its newest Vraylar ad campaign.
Allergan puts Vraylar on blockbuster track with new nod by Carly Helfand Tuesday, May 28, 2019 Allergan, badly in need of good news, finally has some to share with investors who've been clamoring for change.
Pharma TV ad spend beats last year, led by AbbVie and Pfizer by Beth Snyder Bulik Monday, October 15, 2018 With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.
Allergan focuses on biopolar mania in first DTC push for Vraylar by Beth Snyder Bulik Monday, April 9, 2018 Allergan’s new campaign for Vraylar is the antipsychotic's first—and the first DTC push to center on the manic side of bipolar disorder.
Allergan CFO retiring even as company faces 'negative sentiment' by Eric Palmer Monday, September 25, 2017 Allergan says CFO Tessa Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.
Allergan's Vraylar needs 'negative' success to stand out by Carly Helfand Friday, September 9, 2016 Allergan may be able to come up big with new antipsychotic launch Vraylar if the med can shine at treating schizophrenia’s “negative” symptoms. But one analyst isn’t holding his breath.
